TA-MUC1 (tumor-associated MUC1 glycoform)

Class

TA-MUC1-directed antibody-drug conjugate

Pathway

Humanized anti-TA-MUC1 antibody conjugated via a cleavable tetrapeptide linker to a DNA topoisomerase I inhibitor payload (DXd), inducing DNA damage and apoptosis in TA-MUC1-positive tumor cells

TA-MUC1 refers to a tumor-associated form of MUC1, a mucin protein normally found on the surface of epithelial cells such as those lining the gut, lungs, and glands. In healthy tissue, MUC1 is heavily coated with sugar chains (glycosylation) that mask much of the protein and confine it to the surface facing body cavities, away from the bloodstream. In many cancers, this glycosylation pattern becomes abnormal, exposing protein regions and sugar structures that are largely absent from normal cells and are distributed differently on the tumor cell surface. This altered glycoform, TA-MUC1, offers a way to distinguish malignant from healthy tissue. An antibody-drug conjugate (ADC) exploits this by using an antibody that recognizes TA-MUC1 to deliver a cytotoxic payload directly into tumor cells. After the antibody binds and the complex is taken into the cell, a chemical linker is cleaved, releasing a drug that inhibits topoisomerase I, an enzyme required for DNA replication and repair. This causes DNA damage and triggers programmed cell death (apoptosis). This mechanism broadly matters in solid tumors that overexpress aberrantly glycosylated MUC1, including certain breast, ovarian, and other epithelial cancers, where it offers a way to concentrate cytotoxic activity in tumor tissue rather than throughout the body.